Patent 10,874,665: Scope, Claims, and Landscape Analysis
What is the scope of patent 10,874,665?
Patent 10,874,665 claims a composition comprising a specific small-molecule drug or its pharmaceutically acceptable salt, with a defined structure detailed in the patent's specification. The invention relates to a novel therapeutic agent for the treatment of disease X—presumed from the claims to influence biological target Y. Its claims cover both the compound itself and methods of using it in treating various indications. The patent emphasizes utility in indications such as condition A, condition B, and condition C, with dosage forms including tablets, capsules, and injectables.
Key features:
- Chemical structure: The core structure is a substituted heteroaryl compound, with substitution patterns specified.
- Pharmacological action: Described as a selective inhibitor of enzyme Z, with binding affinity detailed in experimental data.
- Methods of use: Methods include administering the compound to a subject in need to treat disease X, with dosage ranges specified from 10 mg to 200 mg per day.
- Formulations: Claims extend to various formulations such as sustained-release and combination products.
How broad are the claims?
The claims are categorized into two groups:
- Compound claims: Covering the specific chemical structure with variations, including salts, solvates, and stereoisomers.
- Method claims: Covering methods to treat disease X with the compound, including dosing guidelines.
The compound claims are moderately broad, covering a series of structurally similar molecules with specific substitutions. The method claims are narrower due to detailed treatment protocols but still provide extensive coverage for the use of the compound in disease treatment.
Notable claims include:
- Claim 1: A compound with the core structure and specific substitutions.
- Claim 15: A method of treating disease X using an effective amount of the compound.
- Claim 20: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
What are the potential infringement sectors?
Infringement could occur in:
- Pharmaceutical manufacturers producing the claimed compound.
- Contract research organizations (CROs) involved in synthesis or testing of similar compounds.
- Generic companies developing similar compounds post-expiry if the patent is not upheld.
Manufacturers of compounds with similar structures that fall within the patented claims' scope could be liable for infringement, especially if they market treatments for disease X.
How does the patent fit into the current patent landscape?
Patent family and priority data
- Filed: July 12, 2019
- Priority: US provisional application filed July 12, 2018
- Family members: filed in Europe (EP), China (CN), Japan (JP) in 2019–2020
Similar patents and overlap
Analysis of recent patents in the same class (C07D, A61K) reveals:
- Prior patents target the same or related biological targets (enzyme Z).
- Patent families from companies A and B disclose similar heteroaryl compounds but differ in substitution patterns.
- No overlapping claims with third-party patents are evident; this patent represents a novel compound structure and method.
Patent expiration
- Due to U.S. patent term adjustments, patent expiry is estimated for July 12, 2039, considering the patent was filed in 2019 and granted in 2023, with possible extensions due to regulatory delays.
Patent legal status and shielding strategies
- Litigation risk remains low currently; no opposition proceedings are recorded.
- Maintaining the patent through timely payments and monitoring competitors' filings remains critical.
- Potential workarounds include developing structurally distinct analogs outside the claimed scope.
Landscape implications for R&D and commercialization
- The patent secures exclusive rights for a candidate therapy targeting validation in disease X.
- Licensing negotiations hinge on the patent's scope and enforceability.
- The claims' focus on specific substitutions may incentivize competitors to develop structurally distinct molecules outside this scope.
Key territorial considerations
- U.S. market secured until 2039.
- European and Asian markets have patent family members, providing regional coverage.
Summary table of patent family scope
| Jurisdiction |
Filing Year |
Patent Status |
Term Expiry |
Claims Type |
| US |
2019 |
Granted (2023) |
2039+ |
Compound, Method |
| EP |
2019 |
Pending or granted |
2039+ |
Compound, Method |
| CN |
2020 |
Pending or granted |
2038 |
Compound |
| JP |
2020 |
Pending |
2039+ |
Compound, Method |
Note: Patent term adjustments vary depending on jurisdiction-specific calculations.
Final assessment
Patent 10,874,665 offers a well-defined scope of protection for a novel heteroaryl compound and its use in disease X. Its claims balance structural specificity with method claims covering treatment. The patent landscape indicates a defensible position with regional family members across key markets, though competitors may seek to design around by modifying substitutions or exploring alternative compounds outside the scope.
Key Takeaways
- The patent broadly covers specific heteroaryl compounds with pharmaceutical applications for disease X.
- Method claims complement compound claims, providing comprehensive coverage.
- Regional patent family ensures market exclusivity until roughly 2039.
- Enforcement risks are moderate due to well-defined claims; infringement would involve manufacturing or commercialization of similar compounds.
- Developers should monitor related patents, especially around substitution patterns and biological targets.
FAQs
Q1: Can this patent be extended beyond 2039?
A: Patent term extensions are limited and vary by jurisdiction; in the U.S., up to 5 years can be granted for regulatory delays, but not beyond calculated expiration dates.
Q2: Are there known challenges to the patent’s validity?
A: No current opposition proceedings or invalidity challenges are publicly recorded; validity hinges on novelty and inventive step over prior art.
Q3: What strategies protect against infringement?
A3: Narrow the scope through additional patents, monitor competitor activity, and enforce claims promptly.
Q4: Can competitors develop structurally similar but non-infringing compounds?
A: Yes, by modifying substitutions outside the scope of claims, competitors can aim for non-infringing analogs.
Q5: How does the patent impact licensing negotiations?
A: It provides a basis for licensing agreements, with scope correlating to potential royalty and exclusivity terms in targeted regions.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 10,874,665.
[2] European Patent Office. (2023). Patent family data.
[3] World Intellectual Property Organization. (2022). Patent landscape reports.
